Immuno-Oncology

London, UK

26 - 27 September 2018

SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area.

Agenda: 15+ engaging presentations/case studies/keynote addresses, including:

• Targeting immune checkpoints with Humabody VH therapeutics
• Tumour mutation burden and the potential of its use as an indication of treatment choice
• Unwanted immunogenicity and functionality testing of immuno-oncology drugs
• New techniques, such as the emerging applications of liquid biopsies

Speakers: Top representation of industry leaders. 15+ leading experts, including:

• James Legg, Crescendo Biologics
• Grace Macaulay, MedImmune
• David Giljohan, Exicure
• Rochana Wickramasinghe, AstraZeneca

Workshops: 2 pre-conference workshops to provide in-depth knowledge on specific topics:

• Strategic Competitive Intelligence in the Immuno-Oncology space
• Could the Microbiome boost Cancer Immuno-Therapy

Keywords: Immune checkpoint inhibitor, antibodies, immune system, IDO inhibitor, Keytruda, T cell function, CAR t cell therapy, oncolytic virus, Therapeutic vaccines, Prophylactic vaccine, Cancer Vaccines, Oncology Pharmacy, chemotherapy, liquid biopsies, Microbiome, anticancer therapy, nktr-214, cd122-biased cytokine, immunogenicity, spherical nucleic acid tlr9

« Back to all meetings